Obesity Drugs and Therapies: Technologies and Global Markets
The global market for obesity treatments should reach over $7.8 billion by 2021 from over $4.3 billion in 2016 at a compound annual growth rate (CAGR) of 12.7% from 2016 to 2021.
- An overview of the global markets for obesity drugs, therapies, and related technologies.
- Analyses of global market trends, with data from 2014, 2015, estimates of 2016, and projects CAGRs through 2021.
- Focus on therapies for obesity that are U.S. FDA approved or allowed through doctors’ permission in the U.S., namely liposuction and bariatric surgery as well as FDA approved medications.
- Bariatric surgery, broken down into four procedures: Gastric Bypass, Sleeve Gastrectomy, Adjustable Gastric Band, and Biliopancreatic Diversion with Duodenal Switch (BPD/DS).
- Information covering obesity pharmaceuticals and surgeries, outlines of various drug and surgery types, a history of the market, and challenges and obstacles as well as those hurdles that have been overcome.
- Evaluation of the market's dynamics, specifically growth drivers, inhibitors, and opportunities.
- A look at the industry's structure, and the landscape of the market.
- Profiles of major players in the field.
SCOPE OF REPORT
The scope of this study encompasses companies that are involved in obesity treatment and prevention of relapse into weight gain. BCC Research analyzes each technology or therapy type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.
Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and an M.A. in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm (in the Research Triangle Park area of North Carolina) that focused on pharmaceuticals and biotechnology. Before joining that firm, she published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.